Stocks · News reference
SCYNEXIS, Inc. announced that its senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston, scheduled for November 9-11, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SCYNEXIS reported positive Phase 1 trial results for its intravenous antifungal candidate SCY-247 and secured up to $214 million in non-dilutive funding from BARDA to support its development.
SCYNEXIS announced it will present information regarding its pipeline candidate SCY-247 at the upcoming IDWeek conference.
SCYNEXIS announced positive Phase 1 results for SCY-247, an intravenous antifungal candidate for invasive fungal diseases. The drug was well-tolerated with no serious adverse events, and doses of 50 mg or higher achieved target exposures identified in preclinical models. The company received a BARDA contract worth up to $214 million and plans to initiate Phase 2 studies in 2027 for both oral and IV formulations.